28228265|t|E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia
28228265|a|Friedreich ataxia (FRDA) is a severe genetic neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin. To date, there is no therapy to treat this condition. The amount of residual frataxin critically affects the severity of the disease; thus, attempts to restore physiological frataxin levels are considered therapeutically relevant. Frataxin levels are controlled by the ubiquitin-proteasome system; therefore, inhibition of the frataxin E3 ligase may represent a strategy to achieve an increase in frataxin levels. Here, we report the identification of the RING E3 ligase RNF126 as the enzyme that specifically mediates frataxin ubiquitination and targets it for degradation. RNF126 interacts with frataxin and promotes its ubiquitination in a catalytic activity - dependent manner, both in vivo and in vitro. Most importantly, RNF126 depletion results in frataxin accumulation in cells derived from FRDA patients, highlighting the relevance of RNF126 as a new therapeutic target for Friedreich ataxia.
28228265	0	9	E3 Ligase	T116,T126	C0077678
28228265	10	16	RNF126	T116,T126	C3657865
28228265	26	39	Ubiquitinates	T044	C1519751
28228265	40	48	Frataxin	T116,T123	C0387678
28228265	50	59	Promoting	T052	C0033414
28228265	64	75	Degradation	T169	C0243125
28228265	77	91	Identification	T080	C0205396
28228265	107	118	Therapeutic	T169	C0302350
28228265	119	125	Target	T169	C1521840
28228265	130	147	Friedreich Ataxia	T047	C0016719
28228265	148	165	Friedreich ataxia	T047	C0016719
28228265	167	171	FRDA	T047	C0016719
28228265	185	192	genetic	T169	C0314603
28228265	193	218	neurodegenerative disease	T047	C0524851
28228265	237	247	expression	T045	C1171362
28228265	255	276	mitochondrial protein	T116,T123	C0949610
28228265	277	285	frataxin	T116,T123	C0387678
28228265	308	315	therapy	T169	C0039798
28228265	319	324	treat	T061	C0087111
28228265	330	339	condition	T080	C0348080
28228265	355	363	residual	T080	C1609982
28228265	364	372	frataxin	T116,T123	C0387678
28228265	396	404	severity	T080	C0439793
28228265	412	419	disease	T047	C0012634
28228265	447	460	physiological	T169	C0205463
28228265	461	469	frataxin	T116,T123	C0387678
28228265	470	476	levels	T080	C0441889
28228265	492	507	therapeutically	T169	C0302350
28228265	508	516	relevant	T080	C2347946
28228265	518	526	Frataxin	T116,T123	C0387678
28228265	527	533	levels	T080	C0441889
28228265	538	551	controlled by	T169	C0332298
28228265	556	583	ubiquitin-proteasome system	T044	C1523807
28228265	596	606	inhibition	T052	C3463820
28228265	614	622	frataxin	T116,T123	C0387678
28228265	623	632	E3 ligase	T116,T126	C0077678
28228265	649	657	strategy	T062	C0035171
28228265	684	692	frataxin	T116,T123	C0387678
28228265	693	699	levels	T080	C0441889
28228265	721	735	identification	T080	C0205396
28228265	743	757	RING E3 ligase	T116,T126	C0077678
28228265	758	764	RNF126	T116,T126	C3657865
28228265	772	778	enzyme	T116,T126	C0014442
28228265	806	814	frataxin	T116,T123	C0387678
28228265	815	829	ubiquitination	T044	C1519751
28228265	849	860	degradation	T169	C0243125
28228265	862	868	RNF126	T116,T126	C3657865
28228265	869	878	interacts	T169	C1704675
28228265	884	892	frataxin	T116,T123	C0387678
28228265	897	905	promotes	T052	C0033414
28228265	910	924	ubiquitination	T044	C1519751
28228265	930	948	catalytic activity	T169	C1264638
28228265	951	960	dependent	T080	C0851827
28228265	974	981	in vivo	T082	C1515655
28228265	986	994	in vitro	T080	C1533691
28228265	1014	1020	RNF126	T116,T126	C3657865
28228265	1021	1030	depletion	T169	C0333668
28228265	1042	1050	frataxin	T116,T123	C0387678
28228265	1051	1063	accumulation	T033	C4055506
28228265	1067	1072	cells	T025	C0007634
28228265	1086	1090	FRDA	T047	C0016719
28228265	1091	1099	patients	T101	C0030705
28228265	1118	1127	relevance	T080	C2347946
28228265	1131	1137	RNF126	T116,T126	C3657865
28228265	1147	1158	therapeutic	T169	C0302350
28228265	1159	1165	target	T169	C1521840
28228265	1170	1187	Friedreich ataxia	T047	C0016719